CLDN18 and neoplasm: The anti-CLDN18.2 ADC exhibited in vitro cytotoxicity to BxPC3/hCLDN18.2 (IC50 = 1.52 nM) and KATO-III/hCLDN18.2 (IC50 = 1.60 nM) tumor cells (Fig. 4a,b).